DK1341774T3 - Kondenserede heteroaromatiske glucokinase-aktivatorer - Google Patents

Kondenserede heteroaromatiske glucokinase-aktivatorer

Info

Publication number
DK1341774T3
DK1341774T3 DK01999565T DK01999565T DK1341774T3 DK 1341774 T3 DK1341774 T3 DK 1341774T3 DK 01999565 T DK01999565 T DK 01999565T DK 01999565 T DK01999565 T DK 01999565T DK 1341774 T3 DK1341774 T3 DK 1341774T3
Authority
DK
Denmark
Prior art keywords
glucokinase activators
condensed heteroaromatic
heteroaromatic glucokinase
condensed
activators
Prior art date
Application number
DK01999565T
Other languages
English (en)
Inventor
Wendy Lea Corbett
Nancy-Ellen Haynes
Robert Francis Kester
Paige Erin Mahaney
Ramakanth Sarabu
Joseph Samuel Grimbsy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1341774T3 publication Critical patent/DK1341774T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
DK01999565T 2000-12-06 2001-11-28 Kondenserede heteroaromatiske glucokinase-aktivatorer DK1341774T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
DK1341774T3 true DK1341774T3 (da) 2006-06-12

Family

ID=22952803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01999565T DK1341774T3 (da) 2000-12-06 2001-11-28 Kondenserede heteroaromatiske glucokinase-aktivatorer

Country Status (21)

Country Link
US (3) US6448399B1 (da)
EP (1) EP1341774B1 (da)
JP (1) JP4109111B2 (da)
KR (1) KR100545431B1 (da)
CN (1) CN1226294C (da)
AR (1) AR031627A1 (da)
AT (1) ATE316965T1 (da)
AU (2) AU2002221902B2 (da)
BR (1) BR0115999A (da)
CA (1) CA2429642C (da)
DE (1) DE60117059T2 (da)
DK (1) DK1341774T3 (da)
ES (1) ES2256340T3 (da)
GT (1) GT200100243A (da)
MX (1) MXPA03005119A (da)
PA (1) PA8534301A1 (da)
PE (1) PE20020753A1 (da)
PT (1) PT1341774E (da)
UY (1) UY27055A1 (da)
WO (1) WO2002046173A1 (da)
ZA (1) ZA200303748B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR101116627B1 (ko) * 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
NZ539013A (en) * 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
MXPA05013733A (es) * 2003-06-20 2006-03-08 Hoffmann La Roche 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
CN101098876A (zh) * 2004-04-02 2008-01-02 诺瓦提斯公司 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法
WO2005095418A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
MXPA06012008A (es) * 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US7745491B2 (en) 2004-08-12 2010-06-29 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
MX2007004560A (es) 2004-10-16 2007-06-08 Astrazeneca Ab Proceso para hacer compuestos de fenoxi benzamida.
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006049304A1 (ja) * 2004-11-02 2006-05-11 Banyu Pharmaceutical Co., Ltd アリールオキシ置換ベンズイミダゾール誘導体
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
BRPI0622261A2 (pt) * 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
JP5281287B2 (ja) 2005-07-13 2013-09-04 Ｍｓｄ株式会社 ヘテロ環置換ベンズイミダゾール誘導体
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008012227A2 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
US20100094009A1 (en) * 2006-12-21 2010-04-15 Mccabe James Novel crystalline compound useful as glk activator
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
BRPI0808267A2 (pt) 2007-03-07 2014-07-22 Kyorin Phamaceutical Co., Ltd "composto representado pela formula geral (1) ou um sal farmeceuticamente aceitável do mesmo; método para o tratamento ou prevenção de diabetes ; uso do composto; composição farmacêutica e composto representado pela formula geral (3)".
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
EP2236498A4 (en) * 2008-01-18 2012-02-22 Astellas Pharma Inc PHENYLACETAMIDE DERIVATIVE
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
PT2275414E (pt) 2008-04-28 2015-09-09 Teijin Pharma Ltd Derivado de amida do ácido ciclopentacrílico
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
EP2331498B1 (en) 2008-08-19 2016-11-09 Janssen Pharmaceutica NV Cold menthol receptor antagonists
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AU2010222589B2 (en) 2009-03-11 2012-08-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116176A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
WO2016185342A1 (en) 2015-05-15 2016-11-24 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
HUP0200396A3 (en) * 1999-03-29 2003-04-28 Hoffmann La Roche Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
CN1476438A (zh) 2004-02-18
CA2429642A1 (en) 2002-06-13
AU2002221902B2 (en) 2006-11-23
PA8534301A1 (es) 2002-08-26
DE60117059D1 (de) 2006-04-13
BR0115999A (pt) 2003-09-30
US20020103199A1 (en) 2002-08-01
DE60117059T2 (de) 2006-10-26
MXPA03005119A (es) 2004-10-15
US6448399B1 (en) 2002-09-10
EP1341774A1 (en) 2003-09-10
CA2429642C (en) 2007-11-20
WO2002046173A1 (en) 2002-06-13
GT200100243A (es) 2002-06-04
PE20020753A1 (es) 2002-08-27
KR20030068555A (ko) 2003-08-21
US20020107396A1 (en) 2002-08-08
AR031627A1 (es) 2003-09-24
JP4109111B2 (ja) 2008-07-02
ATE316965T1 (de) 2006-02-15
UY27055A1 (es) 2002-07-31
EP1341774B1 (en) 2006-02-01
US6441184B1 (en) 2002-08-27
US20020103241A1 (en) 2002-08-01
KR100545431B1 (ko) 2006-01-24
CN1226294C (zh) 2005-11-09
AU2190202A (en) 2002-06-18
PT1341774E (pt) 2006-05-31
JP2004517087A (ja) 2004-06-10
ZA200303748B (en) 2004-08-16
ES2256340T3 (es) 2006-07-16
US6545155B2 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
DK1280801T3 (da) Hydantoinholdige glucokinaseaktivatorer
DK1169312T3 (da) Glucokinaseaktivatorer
DK1242397T3 (da) Trans-olefiniske glucokinaseaktivatorer
CY2015035I2 (el) Ενωσεις πυριμιδινης
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
BR0214972B1 (pt) artigo absorvente.
BR0105361B1 (pt) artigo absorvente.
BR0100865B8 (pt) artigo absorvente.
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
DE60126873D1 (de) PLL-Schaltung
BR0103836B1 (pt) artigo absorvente.
DE60108108D1 (de) Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren
DK1303496T3 (da) Pyrimidinderivater
DE60032869D1 (de) Wasserdispergierbarer absorbierender Artikel
BR0100151B1 (pt) artigo absorvente.
DK1529530T5 (da) Glucokinase påvirkende forbindelser
BR0100961B1 (pt) artigo absorvente.
BR0102028B1 (pt) artigo absorvente.
DE60043769D1 (de) Wasserdispergierbarer absorbierender Artikel
BR0100962B1 (pt) artigo absorvente.
NO20032291D0 (no) Pyrimidinderivater
DK1322651T3 (da) Bicykliske, heteroaromatiske forbindelser
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
BR0212092B1 (pt) artigo absorvente.